Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Turkey

Turkey

The projected revenue in the Other Vaccines market in Turkey is expected to reach US$86.36m in 2024.
This indicates a positive growth trend as the market is projected to show an annual growth rate (CAGR 2024-2029) of 10.08%.
By 2029, the market volume is estimated to reach US$139.60m.
In global comparison, it is noteworthy that United States is expected to generate the highest revenue in the Other Vaccines market, with US$24,730.00m in 2024.
Turkey is experiencing an increasing demand for other vaccines as the government focuses on expanding its immunization program.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Turkey has been showing a steady growth in recent years.

Customer preferences: The Turkish population has been showing a growing interest in preventive healthcare measures, including vaccination. This has led to an increase in demand for Other Vaccines in the country. Additionally, the government has been promoting vaccination programs to improve public health and prevent the spread of diseases.

Trends in the market: One of the major trends in the Other Vaccines market in Turkey is the increasing use of combination vaccines. These vaccines combine multiple antigens in a single dose, reducing the number of injections required and improving patient compliance. Another trend is the growing demand for travel vaccines, as more and more Turkish citizens are traveling abroad for work or leisure.

Local special circumstances: Turkey is a popular tourist destination, attracting millions of visitors every year. This has led to a growing demand for travel vaccines among both local residents and foreign visitors. Additionally, the country has a large young population, which is more susceptible to certain infectious diseases. This has led to a higher demand for vaccines among children and young adults.

Underlying macroeconomic factors: Turkey has a rapidly growing economy, with a large and expanding middle class. This has led to an increase in healthcare spending, including spending on preventive measures such as vaccination. Additionally, the country has a well-developed healthcare system, with a large number of hospitals and clinics offering vaccination services. The government has also been investing heavily in healthcare infrastructure and promoting preventive healthcare measures, which has further boosted the demand for Other Vaccines in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.